Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ESR1 mutation
i
Other names:
ESR1, Era, ESR, NR3A1, ER, ER beta
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2099
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
Guardant360® CDx (54)
Guardant360® CDx (54)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ESR1 mutation
Estrogen Receptor Positive Breast Cancer
ESR1 mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
ESR1 mutation
HER2 Negative Breast Cancer
ESR1 mutation
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
ESR1 mutation
HER2 Negative Breast Cancer
ESR1 mutation
HER2 Negative Breast Cancer
lasofoxifene
Sensitive: C2 – Inclusion Criteria
lasofoxifene
Sensitive
:
C2
lasofoxifene
Sensitive: C2 – Inclusion Criteria
lasofoxifene
Sensitive
:
C2
ESR1 mutation
Breast Cancer
ESR1 mutation
Breast Cancer
AZD9833
Sensitive: C2 – Inclusion Criteria
AZD9833
Sensitive
:
C2
AZD9833
Sensitive: C2 – Inclusion Criteria
AZD9833
Sensitive
:
C2
ESR1 mutation
Breast Cancer
ESR1 mutation
Breast Cancer
FEC
Sensitive: C3 – Early Trials
FEC
Sensitive
:
C3
FEC
Sensitive: C3 – Early Trials
FEC
Sensitive
:
C3
ESR1 mutation
HER2 Negative Breast Cancer
ESR1 mutation
HER2 Negative Breast Cancer
abemaciclib + AZD9833
Sensitive: C3 – Early Trials
abemaciclib + AZD9833
Sensitive
:
C3
abemaciclib + AZD9833
Sensitive: C3 – Early Trials
abemaciclib + AZD9833
Sensitive
:
C3
ESR1 mutation
Breast Cancer
ESR1 mutation
Breast Cancer
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
ESR1 mutation
Breast Cancer
ESR1 mutation
Breast Cancer
CDK4 inhibitor + CDK6 inhibitor
Resistant: C3 – Early Trials
CDK4 inhibitor + CDK6 inhibitor
Resistant
:
C3
CDK4 inhibitor + CDK6 inhibitor
Resistant: C3 – Early Trials
CDK4 inhibitor + CDK6 inhibitor
Resistant
:
C3
ESR1 mutation
HER2 Negative Breast Cancer
ESR1 mutation
HER2 Negative Breast Cancer
nivolumab + ipilimumab
Resistant: C3 – Early Trials
nivolumab + ipilimumab
Resistant
:
C3
nivolumab + ipilimumab
Resistant: C3 – Early Trials
nivolumab + ipilimumab
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login